HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Guiteras Val, P. Articles by Solymoss, B. C. Search for Related Content PubMed PubMed Citation Articles by Guiteras Val, P. Articles by Solymoss, B. C.

The Journal of Thoracic and Cardiovascular Surgery, Vol 86, 878-886, Copyright © 1983 by The American Association for Thoracic Surgery and The Western Thoracic Surgical Association

ARTICLES

Diagnostic criteria and prognosis of perioperative myocardial infarction following coronary bypass

P Guiteras Val, LC Pelletier, MG Hernandez, JM Jais, BR Chaitman, G Dupras and BC Solymoss

To evaluate the incidence of perioperative myocardial infarction (PMI), serial determinations of serum creatine kinase isoenzymes (CK-MB), electrocardiograms (ECGs), and pyrophosphate myocardial scans were performed in 112 patients undergoing isolated coronary bypass grafting. An abnormal increase in total CK-MB liberation (Q greater than 9.8 IU ml-1 kg) occurred in 25 patients (22.3%), new Q waves were present at ECG in 10 patients (8.9%), and the pyrophosphate myocardial scan was abnormal in 13 patients (11.6%). All tests were negative in 81 patients (72.3%). A diagnosis of PMI was established if confirmed by at least two of the techniques; this diagnosis was made in 15 patients (13.4%). The pattern of CK-MB liberation in patients with a PMI, characterized by a high peak and a prolonged release, was significantly different from that of patients without a PMI. The most important predictive factor for PMI was the duration of myocardial ischemia during the operation. Patients who had a PMI had more frequent early complications, and their prognosis at 2 years showed a 51% probability of remaining free of new cardiac events as compared to 96% for the group of patients without a PMI (p less than 0.001). PMI is not a benign complication of coronary bypass, and its detection appears improved by a combination of diagnostic tests.

This article has been cited by other articles:

				A. Kulik, F. D. Rubens, D. Gunning, M. E. Bourke, T. G. Mesana, and M. Ruel Radial Artery Graft Treatment With Phenoxybenzamine is Clinically Safe and May Reduce Perioperative Myocardial Injury Ann. Thorac. Surg., February 1, 2007; 83(2): 502 - 509. [Abstract] [Full Text] [PDF]

				M. C. Engoren, R. H. Habib, A. Zacharias, T. A. Schwann, C. J. Riordan, S. J. Durham, and A. Shah The association of elevated creatine kinase-myocardial band on mortality after coronary artery bypass grafting surgery is time and magnitude limited Eur. J. Cardiothorac. Surg., July 1, 2005; 28(1): 114 - 119. [Abstract] [Full Text] [PDF]

				R. M. Mentzer Jr, R. D. Lasley, A. Jessel, and M. Karmazyn Intracellular sodium hydrogen exchange inhibition and clinical myocardial protection Ann. Thorac. Surg., February 1, 2003; 75(2): S700 - 708. [Abstract] [Full Text] [PDF]

				J. Steuer, L.-G. Horte, B. Lindahl, and E. Stahle Impact of perioperative myocardial injury on early and long-term outcome after coronary artery bypass grafting Eur. Heart J., August 1, 2002; 23(15): 1219 - 1227. [Abstract] [Full Text] [PDF]

				K. Klatte, B. R. Chaitman, P. Theroux, J. A. Gavard, K. Stocke, S. Boyce, C. Bartels, B. Keller, A. Jessel, and for the GUARDIAN Investigators Increased mortality after coronary artery bypass graft surgery is associated with increased levels of postoperative creatine kinase-myocardial band isoenzyme release: Results from the GUARDIAN trial J. Am. Coll. Cardiol., October 1, 2001; 38(4): 1070 - 1077. [Abstract] [Full Text] [PDF]

				D. P. Taggart Biochemical assessment of myocardial injury after cardiac surgery: Effects of a platelet activating factor antagonist, bilateral internal thoracic artery grafts, and coronary endarterectomy J. Thorac. Cardiovasc. Surg., October 1, 2000; 120(4): 651 - 659. [Abstract] [Full Text] [PDF]

				R. Seitelberger, T. Wild, N. Serbecic, S. Schwarzacher, M. Ploner, A. Lassnigg, and B. Podesser Significance of right bundle branch block in the diagnosis of myocardial ischemia in patients undergoing coronary artery bypass grafting Eur. J. Cardiothorac. Surg., August 1, 2000; 18(2): 187 - 193. [Abstract] [Full Text] [PDF]

				M. Carrier, M. Pellerin, L. P. Perrault, B. C. Solymoss, and L. C. Pelletier Troponin levels in patients with myocardial infarction after coronary artery bypass grafting Ann. Thorac. Surg., February 1, 2000; 69(2): 435 - 440. [Abstract] [Full Text] [PDF]

				M. Klein, P.R. Keith, H.-P. Dauben, H.D. Schulte, H. Beckmann, G. Mayer, O. Elert, and E. Gams Aprotinin counterbalances an increased risk of peri-operative haemorrhage in CABG patients pre-treated with Aspirin Eur. J. Cardiothorac. Surg., October 1, 1999; 14(4): 360 - 366. [Abstract] [Full Text] [PDF]

				M GALIÑANES In search of a reliable marker of tissue injury during heart surgery Heart, October 1, 1998; 80(4): 317 - 318. [Full Text]

				K. Suzuki, Y. Sawa, K. Kadoba, T. Takahashi, H. Ichikawa, K. Kagisaki, T. Ohata, and H. Matsuda Early Detection of Cardiac Damage With Heart Fatty Acid-Binding Protein After Cardiac Operations Ann. Thorac. Surg., January 1, 1998; 65(1): 54 - 58. [Abstract] [Full Text] [PDF]

				M. Carrier, L. C. Pelletier, and N. R. Searle Does Retrograde Administration of Blood Cardioplegia Improve Myocardial Protection During First Operation for Coronary Artery Bypass Grafting? Ann. Thorac. Surg., November 1, 1997; 64(5): 1256 - 1262. [Abstract] [Full Text]

				D. T. Mangano Effects of Acadesine on Myocardial Infarction, Stroke, and Death Following Surgery: A Meta-analysis of the 5 International Randomized Trials JAMA, January 22, 1997; 277(4): 325 - 332. [Abstract] [PDF]

				J. H. Lemmer Jr, E. W. Dilling, J. R. Morton, J. B. Rich, F. Robicsek, D. L. Bricker, C. B. Hantler, J. G. Copeland III, J. L. Ochsner, P. O. Daily, et al. Aprotinin for Primary Coronary Artery Bypass Grafting: A Multicenter Trial of Three Dose Regimens Ann. Thorac. Surg., December 1, 1996; 62(6): 1659 - 1668. [Abstract] [Full Text]

				J. H. Levy, R. Pifarre, H. V. Schaff, J. C. Horrow, R. Albus, B. Spiess, T. K. Rosengart, J. Murray, R. E. Clark, P. Smith, et al. A Multicenter, Double-Blind, Placebo-Controlled Trial of Aprotinin for Reducing Blood Loss and the Requirement for Donor-Blood Transfusion in Patients Undergoing Repeat Coronary Artery Bypass Grafting Circulation, October 15, 1995; 92(8): 2236 - 2244. [Abstract] [Full Text]

				P. Menasche, W. R. E. Jamieson, W. Flameng, M. K. Davies, and on behalf of the Multinational Acadesine Study Gro ACADESINE: A NEW DRUG THAT MAY IMPROVE MYOCARDIAL PROTECTION IN CORONARY ARTERY BYPASS GRAFTINGResults of the first international multicenter study J. Thorac. Cardiovasc. Surg., October 1, 1995; 110(4): 1096 - 1106. [Abstract] [Full Text]

				T. H. LEE and L. GOLDMAN Serum Enzyme Assays in the Diagnosis of Acute Myocardial InfarctionRecommendations Based on a Quantitative Analysis Ann Intern Med, August 1, 1986; 105(2): 221 - 233. [Abstract] [PDF]